MONTREAL, October 5, 2021 / PRNewswire / – Innodem Neurosciences today announced that it has signed a multi-year partnership agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to conduct a groundbreaking clinical trial to help people living with multiple sclerosis (MS).
Innodem’s patented AI-based eye tracking software technology is integrated into a mobile app that turns a tablet into a device capable of capturing and analyzing eye movement biomarkers (EMBs) and mapping biomarkers eye gaze (GMB) to help the clinician diagnose and monitor MS. disease progression.
The digital EMB and GMB tests are non-invasive and can be performed in minutes in the clinic waiting room or by the patient at home. Remote self-testing is a major benefit during a pandemic and for people living with MS residing in rural areas who cannot easily access a neurologist.
“The funding from Novartis will fund a carefully designed cross-sectional and longitudinal study in MS that will run until 2027. As a practicing neurologist, I hope the study will validate how Innodem’s technology can help clinicians monitor disease progression as early as possible to improve MS treatment and patient outcomes, ”said Dr. Étienne de Villers-Sidani, cognitive neurologist, founder and CEO of Innodem.
“This partnership is the result of an ongoing collaboration that has been structured over the past two years. It embodies our common goal and our commitment to improve the quality of care for people living with MS around the world, ”added Marc Reeves, co-founder and commercial director of Innodem.
“At Novartis, we are committed to innovating and becoming leaders in healthcare technology. After reviewing existing solutions, we have selected Innodem’s proprietary eye-tracking technology and believe it has the most promise and can easily scale up due to its ease. We anticipate that the trial will confirm its relevance so that more people living with MS and treating clinicians can access it in Canada and across the world “, commented Andrea Marazzi, head of the country’s pharmaceutical organization, Novartis Pharmaceuticals Canada Inc.
During the trial, people living with MS will be tested twice a month and the data will be correlated with the current benchmark Expanded Disability Status Scale (EDSS), Brief International Cognitive Assessment for MS (BICAMS) and Multiple Sclerosis Functional Composite (MSFC) to help clinicians detect subtle changes indicating disease progression that may not appear using magnetic resonance imaging (MRI).
Innodem management believes that the multi-year trial will demonstrate that the new digital EMBs and GMBs can measure these changes accurately, easily and cost effectively. “A clinician whose patient has objective signs of progressive MS may recommend a more appropriate treatment that could, if detected early, prevent that person from developing further disability. There is currently no practical companion diagnostic test for detect progressive MS, and I think EMB and GMB can fill this important gap, ”added Dr de Villers-Sidani.
About INNODEM NEUROSCIENCES
Founded in 2016, Innodem Neurosciences has developed a patented mobile digital biomarker technology for neurodegenerative diseases such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and related disorders, frontotemporal dementia and related disorders and disorders cognitive effects related to cancer (“chemotherapy brain”). This new eye tracking and cognitive testing technology is integrated into a HIPAA / PIPEDA compliant system consisting of an intuitive tablet application connected to a cloud-based AI infrastructure. The app is made up of a series of tasks completed in minutes, where a user’s eye movement is recorded in data sets called Eye Movement Biomarkers (EMB) and Gaze Mapping Biomarkers (GMB). Innodem’s core team, led by cognitive neurologist and CEO, Dr Étienne de Villers-Sidani, is made up of an intersectional group of neuroscientists, software engineers, data scientists, healthcare professionals and serial entrepreneurs. The company’s mission is to provide simpler means of performing remote testing for all stages of neurodegenerative diseases and cancer-related cognitive impairment to improve quality of care and patient outcomes, to unprecedented levels of usability and cost-effectiveness for the global healthcare system. For more information, please visit www.innodemneurosciences.com
Contact person: Valérie Gonzalo, AGO Communications, 514-923-1549, [email protected]
SOURCE Innodem Neurosciences